NVAX NOVAVAX INC
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1000694 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-61.3%
TTM net income YoY-122.5%
TTM EPS YoY-125.9%
Revenue 3-yr CAGR-26.8%
Net income 3-yr CAGR—
Margins
Gross margin78.0%
Operating margin-21.2%
Net margin-18.6%
FCF margin-59.2%
EBITDA margin-17.7%
Returns
ROE—
ROA-7.4%
ROIC (approx.)—
Asset turnover0.40x
Leverage & solvency
Liabilities / assets124.4%
Debt / equity—
Current ratio2.15x
Interest coverage-4.01x
Cash quality & payout
Operating cash flow / net income3.11x
Accruals ratio15.7%
Payout ratio—
Capex / revenue1.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.12B | $682.16M | $983.71M | $1.98B | $1.15B |
| Cost of revenue | $73.04M | $202.74M | $343.77M | $902.64M | $0 |
| Gross profit | $1.05B | $479.42M | $639.94M | $1.08B | $1.15B |
| R&D expense | $342.32M | $391.17M | $737.50M | $1.24B | $2.53B |
| SG&A expense | $157.48M | $337.19M | $468.95M | $488.69M | $298.36M |
| Operating income | $452.80M | -$248.93M | -$566.51M | -$644.74M | -$1.69B |
| Interest expense | $22.55M | $20.07M | $14.42M | $19.88M | $21.13M |
| Pretax income | $442.17M | -$176.62M | -$543.03M | -$653.65M | -$1.71B |
| Income tax | $1.86M | $10.88M | $2.03M | $4.29M | $29.21M |
| Net income | $440.30M | -$187.50M | -$545.06M | -$657.94M | -$1.74B |
| EBITDA | $480.80M | -$200.93M | -$525.51M | -$615.74M | -$1.67B |
| EPS (basic) | 2.72 | -1.23 | -5.41 | -8.42 | -23.44 |
| EPS (diluted) | 2.58 | -1.23 | -5.41 | -8.42 | -23.44 |
| Weighted avg. shares (diluted) | 173.10M | 152.19M | 100.77M | 78.18M | 74.40M |
| Balance sheet | |||||
| Cash & equivalents | $240.63M | $545.29M | $568.50M | $1.35B | $1.53B |
| Short-term investments | $494.45M | $392.89M | $0 | — | $0 |
| Receivables | — | — | — | — | $454.99M |
| Inventory | $11.54M | $8.75M | $41.70M | $36.68M | $8.87M |
| Current assets | $978.28M | $1.13B | $1.14B | $1.70B | $2.16B |
| PP&E, net | $44.80M | $138.41M | $305.77M | $294.25M | $225.74M |
| Goodwill | $113.46M | $107.48M | $127.45M | $126.33M | $131.48M |
| Intangibles | — | — | — | — | $4.77M |
| Total assets | $1.18B | $1.56B | $1.80B | $2.26B | $2.58B |
| Current liabilities | $459.95M | $1.15B | $1.64B | $2.46B | $2.39B |
| Long-term debt | $244.21M | — | — | — | — |
| Total debt | $244.21M | — | — | — | — |
| Total liabilities | $1.30B | $2.18B | $2.51B | $2.89B | $2.93B |
| Shareholders' equity | -$127.75M | -$623.84M | -$716.93M | -$634.08M | -$351.67M |
| Net debt | $3.58M | — | — | — | — |
| Shares outstanding | 162.58M | 160.42M | 139.51M | 86.04M | 75.84M |
| Cash flow statement | |||||
| Operating cash flow | -$244.63M | -$87.26M | -$713.97M | -$415.94M | $322.95M |
| Capital expenditure | $5.56M | $13.06M | $53.77M | $89.06M | $54.50M |
| Free cash flow | -$250.19M | -$100.32M | -$767.74M | -$504.99M | $268.44M |
| Investing cash flow | -$78.27M | -$204.04M | -$58.81M | -$92.98M | $100.15M |
| Financing cash flow | $27.74M | $260.58M | $4.47M | $324.99M | $461.71M |
| Depreciation & amortization | $28.00M | $48.00M | $41.00M | $29.00M | $13.00M |
| Stock-based compensation | $36.02M | $48.15M | $85.36M | $130.30M | $183.63M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.